Glenmark Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1678.9, up 2.5% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.11% on the day, quoting at 24726.7. The Sensex is at 80745.92, down 0.07%. Glenmark Pharmaceuticals Ltd has risen around 17.43% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 9.31% in last one month and is currently quoting at 22374.25, up 0.85% on the day. The volume in the stock stood at 7.48 lakh shares today, compared to the daily average of 10.77 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1675.75, up 2.33% on the day. Glenmark Pharmaceuticals Ltd is up 121.2% in last one year as compared to a 27.48% spurt in NIFTY and a 47.45% spurt in the Nifty Pharma index.The PE of the stock is 28.57 based on TTM earnings ending June 24.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 1633.65, up 4.33% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 24574.45. The Sensex is at 80465.57, up 0.04%. Glenmark Pharmaceuticals Ltd has added around 14.27% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 7.84% in last one month and is currently quoting at 22106.5, up 0.69% on the day. The volume in the stock stood at 17.75 lakh shares today, compared to the daily average of 10.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1630.45, up 3.94% on the day. Glenmark Pharmaceuticals Ltd is up 110.78% in last one year as compared to a 26.71% gain in NIFTY and a 45.17% gain in the Nifty Pharma index.The PE of the stock is 30.99 based on TTM earnings ending March 24.Powered by Capital Market - Live

The solution is the generic version of 'Pataday Twice Daily Relief', which is distributed by Alcon Laboratories, Inc. The registered trademark 'Pataday' is owned by Novartis AG. Olopatadine belongs to a group of medicines called antihistamines. It is used to treat seasonal allergic conjunctivitis (infection, itching, redness, and swelling of the eye) caused due to pollens, dust, animal fur, and other allergens. According to Nielsen, syndicated data for the latest 52 weeks' period ending 13 July 2024, the 'Pataday Twice Daily Relief' (OTC) market achieved annual sales of approximately $26.4 million. Fabio Moreno, Head ' OTC sales & marketing, Glenmark Pharmaceuticals Inc. said, 'We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. The drug maker reported consolidated net profit of Rs 340.27 crore in Q1 FY25, significantly higher from Rs 14.48 crore in Q1 FY24. Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live

Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday'2 Twice Daily Relief. According to Nielsen' syndicated data for the latest 52 weeks' period ending 13 July 2024, the Pataday' Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million. Commenting on the launch, Fabio Moreno, Head - OTC Sales & Marketing, Glenmark Pharmaceuticals Inc. said, 'We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality overthe-counter solutions for our customers.'Powered by Capital Market - Live

Revenue from operations increased 6.85% year on year (YoY) to Rs 3,244.19 crore in the quarter ended 30 June 2024. Profit before tax stood at Rs 462.33 crore in June 2024 quarter, steeply higher than Rs 151.40 crore posted in corresponding quarter previous year. EBITDA stood at Rs 588.2 crore in first quarter of FY25, registering a growth of 34.5% on YoY basis. During the quarter, EBITDA margin improved to 18.1% as against 14.4% in Q1 FY24. In India, sales from the formulation business jumped 11.9% to Rs 1,196.2 crore in Q1 FY25 as compared with Rs 1,069.3 crore recorded in corresponding quarter previous year. In terms of secondary sales, Glenmark's India business continued to outperform the overall industry in terms of growth. As per IQVIA June 2024 data, Glenmark's India formulation business recorded growth of 11.3%. The North America business registered revenues from the sale of finished dosage formulations of Rs 780.8 crore ($93.6 million) for the first quarter of FY25, up 3.32% as against revenue of Rs 755.7 crore ($91 million) recorded in Q1 FY24. The overall business growth remained challenging on account of lack of new product launches and delay in scale-up of recent launches. During Q4 FY24, revenues from the RCIS, LATAM, MEA & APAC (RoW) region were Rs 570.8 crore as against Rs 552.8 crore for the previous corresponding quarter, recording growth of 3.26%. Glenmark Europe's operations revenue for the Q1 of FY 2024-25 was increased 21.4% YoY to Rs 695.7 crore. The company's European operations continued growth momentum driven by all markets. Glenn Saldanha, chairman and managing director, Glenmark Pharmaceuticals, said, 'Our strong start to the new financial year reflects our robust revenue growth across key regions and solid operational performance, leading to a significantly improved margin profile. Our India business continues to excel, outpacing the Indian Pharma Market with our expertise in our core therapeutic areas, while Europe build on its FY24 success with further growth in the branded segment. RYALTRIS remains a major global growth driver, achieving high double-digit market shares in multiple regions. As we look ahead, we are committed to launching innovative products, including Envafolimab and Winlevi, and are confident of our trajectory towards meeting our FY25 objectives.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with presence across specialty, generics and OTC businesses. Powered by Capital Market - Live

The domestic equity benchmarks traded with major gains in early trade, following positive momentum in global markets. The Nifty traded near the 24,400 level. All the sectoral indices on NSE were in the green with IT, auto and media shares gaining the most. At 09:25 IST, the barometer index, the S&P BSE Sensex jumped 861.69 points or 1.04% to 79,934.45. The Nifty 50 index added 251.20 points or 1.04% to 24,394.95. In the broader market, the S&P BSE Mid-Cap index gained 1% and the S&P BSE Small-Cap index rose 1.02%. The market breadth was strong. On the BSE, 2,226 shares rose and 816 shares fell. A total of 103 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 2,595.27 crore, while domestic institutional investors (DIIs), were net buyers to the tune of Rs 2,236.21 crore in the Indian equity market on 14 August 2024, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper jumped 1.98% to 6.994 as compared with previous close 6.858. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 83.9450, compared with its close of 83.9400 during the previous trading session. MCX Gold futures for 5 September 2024 settlement advanced 0.24% to Rs 70,040. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies shed 0.04% to 102.92. The United States 10-year bond yield fell 0.59% to 3.911. In the commodities market, Brent crude for October 2024 settlement shed 20 cents or 0.25% to $80.84 a barrel. Stocks in Spotlight: Glenmark Pharmaceuticals slipped 3.58%. The company's consolidated net profit jumped 96.53% to Rs 340 crore in Q1 FY25 as compared with Rs 173 crore in Q1 FY24. Revenue increased 6.85% YoY to Rs 3,244 crore during the quarter. Ola Electric Mobility zoomed 14.74%. The firm reported consolidated net loss of Rs 347 crore in Q1 FY25 as compared with net loss of Rs 267 crore in Q1 FY24. Revenue jumped 32% YoY to Rs 1,644 crore in Q1 FY24. Entero Healthcare Solutions rose 1.21% after the company's consolidated net profit surged to Rs 20.5 crore in Q1 FY25 from Rs 6.4 crore in Q1 FY24. Revenue increased 22.02% YoY to Rs 1,097 crore during the quarter. Global Markets: Asian stocks surged on Friday, buoyed by upbeat US economic data that tempered recession fears. Robust US retail sales and a decline in jobless claims fueled a rally in global equities and sent bond yields higher. These positive economic indicators, following the benign inflation report earlier in the week, have strengthened expectations for interest rate cuts by the Federal Reserve. However, market sentiment suggests these cuts will be gradual. US stocks closed sharply higher on Thursday, with the Dow Jones Industrial Average gaining 1.4%, the S&P 500 rising 1.6%, and the Nasdaq Composite jumping 2.3%. Retail sales increased 1.0% after a downwardly revised 0.2% drop in June, easing fears of a sharp economic slowdown fanned by a jump in the unemployment rate last week. Initial claims for state unemployment benefits dropped 7,000 to a seasonally adjusted 227,000 for the week ended Aug. 10, the Labor Department said.Powered by Capital Market - Live

Net profit of Glenmark Pharmaceuticals rose 126.95% to Rs 340.27 crore in the quarter ended June 2024 as against Rs 149.93 crore during the previous quarter ended June 2023. Sales rose 7.50% to Rs 3223.30 crore in the quarter ended June 2024 as against Rs 2998.47 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3223.302998.47 7 OPM %18.2514.59 - PBDT580.12345.46 68 PBT462.33203.42 127 NP340.27149.93 127 Powered by Capital Market - Live

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live